Depigmentation Outcomes in Pigmented Oral Lichen Planus Managed With Mycophenolate Mofetil Authors: Tania Biswas, Atul Anand Bajoria, Noureen Nahar, Pallawi Sinha, Jitendra Sharan, Smriti K C Basynat Published: 2026 ABSTRACT ABSTRACTPigmented oral lichen planus (OLP) is a chronic, immune‐mediated mucosal disorder associated with dark black or brown discoloration secondary to the excess melanin deposition. This medical condition is often accompanied by the typical white (reticular) or red (erosive) OLP features and is refractory to conventional therapy. We report a case of OLP which was successfully managed with oral mycophenolate mofetil (MMF), resulting in significant symptomatic relief and reduction of hyperpigmentation. MMF offers a safe and effective systemic option for persistent pigmented OLP.Keywords: hyperpigmentation, immunosuppressants, mycophenolate mofetil, oral lichen planus, refractory lesions Introduction Oral lichen planus (OLP) is a persistent inflammatory disorder that targets the mucous membranes within the mouth. It manifests as white, lace‐like patches or red, inflamed tissues, often leading to considerable discomfort. The precise cause of OLP is not fully understood but is thought to involve an immune‐mediated process, where the immune system erroneously attacks the cells of the mucous membranes [1]. Among the different clinical variants of lichen planus, a unique pigmented type known as lichen planus pigmentosus (LPP) has been recognized. This form was first described by Bhutani et al. in 1974 in India, where they coined the term to characterize its distinct features which are marked by a gradual onset and the development of small, dark brown to black macules, most commonly appearing on areas of the skin exposed to sunlight, with these macules potentially coalescing, forming larger areas of hyperpigmentation. While LPP predominantly affects the face, trunk, and upper limbs, involvement of the oral mucosa is uncommon, typically spares the palms, soles, and nails [2, 3]. Management of OLP is complicated by its chronic relapsing nature, with alternating phases of remission and exacerbation with topical corticosteroids as the first‐line treatment, whereas topical immunomodulators such as tacrolimus and pimecrolimus serve as alternatives in refractory cases and systemic corticosteroids are avoided for their side effects on long term use. These drawbacks underscore the importance of exploring systemic nonsteroidal immunomodulators (SNSIs) as potential therapeutic agents that can modify immune responses with a more favorable safety profile [4]. Mycophenolate mofetil (MMF) suppresses lymphocyte proliferation and exerts immunomodulatory effects that may influence melanocyte survival by activating the WNT/β‐catenin signaling pathway. Although topical MMF has shown promise in inducing partial re‐pigmentation in vitiligo, its mechanism of action on melanogenesis remains unknown. Based on this, Guo et al. (2025) investigated the potential use of MMF to reverse hydroquinone‐induced depigmentation, highlighting its emerging therapeutic relevance in managing pigmentary disorders [5]. Case Presentation History and Examination A 27‐year‐old male patient reported to the Dental Outpatient Department with chief complaint of burning sensation on the inner aspect of both cheeks for the past three weeks with consumption of hot oily or spicy foods. On self‐examination, he noticed the presence of white zig zag mesh like lines inside both cheeks, surrounded by a blackish pigmented area. He denied any history of systemic illness, drug intake, or deleterious oral habits. Intraoral examination revealed an ill‐defined lesion measuring approximately 5 × 4 cm on the left posterior buccal mucosa, extending from the region of the left mandibular first molar to the pterygomandibular raphe. The lesion appeared as a hyperpigmented patch interspersed with radiating white striations extending into the adjacent mucosa. The surface was non‐scrapable, intact, and non‐ulcerated. On the right buccal mucosa, a smaller lesion measuring approximately 2 × 2 cm was noted adjacent to the premolar region, with similar clinical features (Figure 1). Based on the presentation, a provisional diagnosis of a reticular pattern of oral lichen planus with pigmentation was made. Clinical presentation of the pigmented oral lichen planus at first visit. (A) Right cheek mucosa, and (B) Left cheek mucosa. Investigations, Treatment, and Follow‐Up An incisional biopsy was advised to obtain a definitive histopathological diagnosis. However, the patient was reluctant to undergo any invasive procedure despite detailed counseling regarding its importance. Considering the patient's apprehension, a conservative approach was adopted. He was initiated on topical application of clobetasol propionate 0.05% w/w ointment, applied thrice daily for 2 weeks and recalled for follow‐up thereafter. As the patient reported after 2 weeks, a new lesion was identified on the right dorsum of the tongue during examination. The lesion appeared as a circular, diffuse white patch with areas of depapillation, producing a slightly irregular surface, non‐scrapable, with ill‐defined borders merging into the surrounding mucosa, and showed no ulceration or secondary changes with a 50% reduction in burning sensation noted. Apart from that, no improvement was observed in the existing hyperpigmented lesions (Figure 2). Two weeks follow up clinical presentation of patient following treatment with 0.5% w/v Clobetasol Propionate. No improvement in pigmented oral lesion of right and left cheek mucosa (A and C), and (B) Depapillation of the dorsal surface of the tongue. Consequently, topical therapy was discontinued, and routine investigations, including a complete blood count with a peripheral smear, G6PD activity, and liver function tests, were performed; all results were within normal limits (Table 1). Considering the persistence of lesions and development of new lesions, the patient was prescribed mycophenolate mofetil 500 mg once daily at bedtime with a follow‐up after 2 weeks. On follow‐up after 2 weeks, improvement in the hyperpigmented areas was noted, with a visible reduction along with considerable reduction in burning sensation of oral cavity noted with 90% regression in signs and symptoms (Figure 3). Furthermore, continuation of conservative management with regular monitoring was advised to the patient in which he remained symptom‐free for 6 months during the follow‐up period. TABLE 1Routine blood investigations (Includes CBC, liver function test, and G6PD activity test).ParameterResultReference valueComplete blood countHemoglobin16.2 g/dL13.8–17.2 g/dLRBC Count5.03 × 106μL4.7–6.1 × 106μLPCV48.1%40%–54%MCV95.6 fL/μm3 80–100 fL/μm3 MCH32.2 pg27–33 pgMCHC33.7 g/dL32–36 g/dLRDW‐CV13.4%11.5%–14.5%RDW‐SD45.5 fL39–46 fLPlatelet count164 × 103 μ L150–450 × 103 μ LMPV11.8 fL39–46 fLWBC count9.4 × 103 μ L150–450 × 103 μ LNeutrophil69.7%40%–80%Lymphocyte22.1%20%–40%Monocyte6.9%2%–8%Eosinophil1.1%Less than 5%Basophil0.2%0.5%–1%Absolute Neutrophil Count6.6 × 103 μ L1.5–8 × 103 μ LAbsolute Lymphocyte Count2.1 × 103 μ L1–4.5 × 103 μ LAbsolute Monocyte Count0.65 × 103 μ L0–8 × 103 μ LAbsolute Eosinophil Count0.1 × 103 μ L0–6 × 103 μ LAbsolute Basophil Count0.0 × 103 μ L0–2 × 103 μ LLiver function testSerum Bilirubin (Total)0.86 mg/dL0.1–1.2 mg/dLSerum Bilirubin (Direct)0.17 mg/dL0.0–0.3 mg/dLSerun Bilirunin (Indirect)0.69 mg/dL0.2–0.8 mg/dLSerum SGOT17.5 U/L8–45 U/LSerum SGPT22.6 U/L7–58 U/LSerum Alkaline Phosphate85 U/L44–147 U/LSerum Gamma GT15.3 U/L0–30 U/LSerum Total Protein8.03 g/dL6–8.3 g/dLSerun Albumin4.43 g/dL3.5–5 g/dLSerum Globulin3.60 g/dL2–3.5 g/dLA/G Ratio1.231.1:1–2.5:1G6PD activity testG6PD Activity11.1 U/g Hb3–15 U/g Hb Routine blood investigations (Includes CBC, liver function test, and G6PD activity test). Four weeks follow up clinical presentation of the lesion following mycophenolate mofetil 500 mg once daily usage. Marked reduction in the pigmented lesion of the right and left cheek mucosa (A, C), and (B) Repapillation of the dorsal surface of the tongue. Discussion Mycophenolate mofetil (MMF) exerts its therapeutic effects primarily through the selective, noncompetitive, and reversible inhibition of inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanine nucleotides. Since lymphocytes rely heavily on this pathway for proliferation, MMF suppresses T‐ and B‐cell activation and antibody formation, thereby reducing inflammatory cytokine production and limiting immune‐mediated tissue injury while sparing other cells that use salvage pathways; it also impairs leukocyte recruitment, which reduces chronic inflammation in oral lesions and thereby indirectly influences melanocyte activity, which explains the depigmentation observed in some cases (Figure 4), thus showing its therapeutic role in various immune‐mediated muco‐cutaneous conditions [6]. Schematic illustration represents the mode of action of mycophenolate mofetil in oral pigmented lichen planus. Topical MMF therapy is noted to activate repigmentation through modulation of immunomodulatory and melanogenic pathways. In addition to its immunosuppressive effects, Guo et al. (2025) demonstrated that MMF reversed hydroquinone‐induced depigmentation by increasing melanocyte numbers and upregulating melanogenic genes such as TYR and MITF, along with reactivation of tyrosinase activity. These findings suggest that MMF may contribute to repigmentation through dual mechanisms: suppression of immune‐mediated damage and restoration of melanocyte function [5]. This combined effect may explain the clinical improvement and reduction in pigmentation observed in our case. In clinical practice, systemic corticosteroids can also produce rapid clinical improvement in painful or widespread oral lichen planus but adverse effects on long‐term use and relapse on dose reduction have been observed in long‐term and randomized control studies [7]. Given these limitations, Pedraça et al. (2023) comprehensively evaluated systemic nonsteroidal immunomodulators (SNSIs) for the management of oral lichen planus, underscoring their importance in refractory cases, with methotrexate and dapsone demonstrating the strongest evidence in achieving maximum clinical improvement. Although mycophenolate mofetil has been less studied, it emerged as a potential alternative in refractory cases, supporting the judicious use of systemic immunomodulators in severe and recalcitrant forms of OLP, as in our case [4]. With respected to pigmented related safety, Silva et al. reviewed 19 studies and found that long‐term use of hydroxychloroquine or chloroquine can cause oral pigmentation, most commonly on the hard palate, typically bluish‐gray in color, often appearing after at least 6 months and with longer treatment durations and moderate daily doses with risk increasing with higher dose and longer use. In contrast, mycophenolate mofetil (MMF) has not been reported to cause similar oral pigmentation. While MMF's primary role is in stabilizing autoimmune activity (e.g., in vitiligo or lichen planus) rather than inducing pigmentation, its lack of documented pigment‐inducing effects may position it as a preferable option. This offers a useful clinical distinction: in a patient susceptible to pigmented sequelae, whereas MMF may represent a safer alternative from a pigmentation‐risk perspective [8]. Mycophenolate mofetil (MMF) has emerged as a promising therapeutic option for acquired dermal macular hyperpigmentation (ADMH), including lichen planus pigmentosus (LPP), due to its immunomodulatory effects. Beyond OLP, Bishnoi et al. (2021) demonstrated that oral MMF significantly reduced the dermal pigmentation area and severity index in patients with ADMH. Given these mechanisms and the observed clinical benefits in ADMH, MMF presents a rational treatment approach for LPP‐related pigmentation, especially refractory cases [9]. Evidence from studies by Duplaine et al. (2022) reported a retrospective case series evaluating mycophenolate mofetil (MMF) in five patients in refractory nail lichen planus (NLP) cases with improvement noted with higher doses and longer treatment duration [10] and similarly, Frieling et al. (2003) demonstrated complete or marked remission in patients with severe disseminated or erosive lichen planus following MMF therapy, with sustained responses observed during long‐term follow‐up. Importantly, MMF was well tolerated in these studies, with minimal adverse effects reported [11]. Mycophenolate mofetil (MMF) was employed in our case for the management of severe, recalcitrant oral lichen planus (OLP), demonstrating significant clinical improvement and favorable tolerance within weeks of initiating MMF, including a marked reduction in lesion size, erythema, and pain, with no major adverse effects reported. These findings are consistent with the current literature summarized by Aljohani et al. (2025), which highlights MMF's effectiveness in inducing remission in autoimmune and inflammatory oral mucocutaneous diseases, including OLP, along with its steroid‐sparing benefits and utility in refractory cases [12]. Furthermore, our observations align with the retrospective case series by Wee et al. (2012), which demonstrated that MMF achieved remission or disease control in the majority of patients with recalcitrant mucocutaneous lichen planus, including oral involvement, and was well tolerated over long‐term follow‐up. This parallel between our clinical outcome and the reported efficacy in the Wee et al. cohort reinforces MMF's role as an effective systemic immunomodulator in refractory OLP, providing sustained symptomatic relief [13]. In addition, a randomized clinical trial by Goel et al. (2021) investigated the effects of mycophenolate mofetil, methotrexate, and pimecrolimus on CDK4 and p16 expression in erosive OLP with them significantly reducing cytoplasmic CDK4 levels, while systemic therapies with methotrexate and MMF were particularly effective in reducing nuclear CDK4 expression. Notably, MMF also resulted in a significant decrease in cytoplasmic p16 expression, suggesting its role in modulating dysregulated cell‐cycle pathways in OLP. This study further confirms the favorable tolerability and safety profile of MMF compared to methotrexate, underscoring its promise as a long‐term therapeutic option for recalcitrant cases, similarly noted in our case [14]. Conclusion In conclusion, mycophenolate mofetil (MMF) demonstrates significant potential as a safe and effective systemic therapy for pigmented oral lichen planus, particularly in refractory cases. Its immunomodulatory action, through selective inhibition of lymphocyte proliferation and attenuation of inflammatory pathways, not only stabilizes disease activity but may also contribute to depigmentation by indirectly modulating melanocyte function. Evidence from clinical studies and case reports supports MMF's role in achieving symptomatic relief, lesion regression, and long‐term disease control with a favorable safety profile. Given the challenges in managing persistent hyperpigmented and recalcitrant OLP lesions, MMF represents a rational and targeted therapeutic option, warranting further investigation through larger, controlled trials to establish standardized dosing, duration, and long‐term outcomes. Author Contributions Tania Biswas: conceptualization, resources, writing – original draft. Atul Anand Bajoria: conceptualization, methodology, supervision, validation, writing – review and editing. Noureen Nahar: conceptualization, methodology, resources, supervision, writing – original draft. Pallawi Sinha: conceptualization, methodology, resources, supervision, writing – original draft. Jitendra Sharan: project administration, resources, supervision, validation, writing – review and editing. Smriti K. C. Basynat: project administration, resources, writing – review and editing. Funding The authors have nothing to report. Consent Informed written consent was obtained from the patient for publication of his images. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement Datasets related to this article will be available upon request to the corresponding author. References Associated Data Data Availability Statement Datasets related to this article will be available upon request to the corresponding author.